India's hidden health crisis: Genetic blood disorders plague children under 12
India is facing a hidden health crisis among children: the alarming rate of inherited blood disorders.New data from Metropolis Healthcare, a diagnostic laboratory chain, has found that more than 1 in 4 children from 0 to 12 suspected of having a blood disorder were found to carry inherited haemoglobin diseases.The findings are based on a three-year study conducted between 2021 and 2024.advertisement
The study screened nearly 20,000 children who showed signs of haemoglobinopathies, a group of inherited conditions that affect red blood cells and can lead to chronic anaemia, fatigue, delayed growth, and vulnerability to infections.Around 28.4% of these children tested positive for a haemoglobin disorder, raising serious questions about the reach and effectiveness of India's paediatric and maternal health infrastructure.The two most common conditions identified were beta-thalassaemia trait (38.7%) and sickle cell disease (30%).
Thalassemia.
Beta-thalassaemia affects the body's ability to produce enough red blood cells, while sickle cell disease alters the shape of red blood cells, often causing severe pain, frequent infections, and life-threatening complications.advertisementEven more concerning is that over half of the affected children were below the age of three, thus, highlighting the desperate need for early screening and preventive interventions."Our findings reveal an urgent public health concern. Early detection through prenatal and newborn screening can dramatically alter disease outcomes," said ,' said Dr. Smita Sudke, Chief of Laboratory, Pune & Rest of Maharashtra at Metropolis and lead author of the study.REGIONAL DISPARITY AND GENETIC RED FLAGSThe data also reveal regional differences in the spread of these disorders, suggesting that blanket screening policies may not be enough.The Northeast had the highest positivity rate at 48.44%, largely due to a high prevalence of Haemoglobin E (HbE).
The data also reveal regional differences in the spread of these disorders, suggesting that blanket screening policies may not be enough.
Central India saw sickle cell disease dominate, with a positivity rate of 37.36%.Southern states recorded a 34.09% prevalence of various haemoglobinopathies.Meanwhile, Western and Northern India showed widespread cases of beta-thalassaemia trait.Such data, say experts, make a compelling case for region-specific screening protocols and stronger integration of genetic testing into routine healthcare services, especially for expectant mothers and young children.advertisementMOLECULAR TESTING IS A GAME-CHANGERBeyond identifying the burden, the study highlights the role of molecular diagnostics in catching what traditional tests often miss.Techniques such as Next-Generation Sequencing (NGS), Sanger sequencing, and Gap-PCR are transforming how India can detect, diagnose, and manage inherited blood disorders.
Beyond identifying the burden, the study highlights the role of molecular diagnostics in catching what traditional tests often miss. ()
"NGS can look deeply into genes like HBB, HBA1, and HBA2 to detect even the smallest or rarest mutations. This allows for early intervention, even before symptoms show up, and helps guide families in reproductive planning and disease management," explained Dr. Kirti Chadha, Chief Scientific and Innovation Officer at Metropolis Healthcare.An earlier nationwide study by Metropolis, involving over 65,000 individuals, also underlined how genetic sequencing can detect both common and rare mutations in haemoglobin genes, essential knowledge in a country where carrier status often goes undiagnosed until it's too late.advertisementNEED FOR PUBLIC AWARENESSIndia is home to nearly 25% of the world's thalassaemia burden. Despite this, genetic testing remains largely out of reach for many, and awareness of these disorders is low, especially in rural regions.Study experts are calling for national-level policy changes, including:Prenatal and newborn screening programsMandatory genetic counsellingAffordable access to molecular testing, especially in high-prevalence zonesThe message is clear: without early detection and proactive screening, thousands of children will continue to suffer the life-altering effects of preventable genetic conditions.As India grapples with a rising non-communicable disease burden, inherited blood disorders must not remain in the shadows.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hindustan Times
5 days ago
- Hindustan Times
ICMR-NIV Pune inaugurates high performance computing facility
PUNE The Indian Council of Medical Research (ICMR) launched its first High Performance Computing (HPC) facility at the ICMR–National Institute of Virology (NIV) Pune on Saturday. The advanced system, named NAKSHATRA, was inaugurated by Dr Rajiv Bahl, secretary of the department of health research and director general of ICMR. The facility has been developed under the Pradhan Mantri Ayushman Bharat Health Infrastructure Mission (PM-ABHIM) as part of a new project called 'High Performance Computing Next Generation Sequencing (NGS) Hub'. It is designed to boost the country's ability to process large volumes of genomic and bioinformatics data—an area that faced challenges during the Covid-19 pandemic due to limited computing resources. Speaking at the inauguration, Dr Bahl praised the institute for its timely and strategic step towards 'Viksit Bharat 2047' vision by strengthening the country's genomic surveillance and data analysis capacity. He highlighted how enhanced computing resources are crucial in preparing for technology driven pandemic preparedness and future public health emergencies. Dr Naveen Kumar, director, ICMR-NIV, emphasized the critical role the HPC cluster will play in supporting rapid, data-driven responses to outbreaks. The newly commissioned HPC cluster features twelve compute nodes, offering a total of 700 cores and 1 petabyte of storage. The infrastructure is tailored to support complex bioinformatics workflows including next-generation sequencing (NGS), transcriptomics, phylogenetics, metagenomics, and structural bioinformatics. Initially, the facility will serve five ICMR institutes across the country, acting as a central repository for sequencing data and extending support to Viral Research and Diagnostic Laboratories (VRDLs) in the near future. This makes the Pune-based institute a critical hub for outbreak investigations and pandemic preparedness, with the potential to accelerate AI-driven drug and vaccine discovery.
&w=3840&q=100)
Business Standard
28-05-2025
- Business Standard
Could gene therapy end thalassemia? China's breakthrough sparks hope
Can a single shot rewrite a child's genetic fate? In a groundbreaking trial, doctors in China have used gene therapy to successfully treat children with thalassemia, a life-threatening inherited blood disorder that has long burdened families with frequent transfusions and lifelong medical care. As reported by media reports, one-time treatment using gene-edited stem cells has enabled multiple children to live transfusion-free for over a year. The promise is immense as it might offer a potential cure for a disease that affects millions across the globe. What is thalassemia and how does it impact the body? According to the Cleveland Clinic, an American nonprofit academic medical center based in Cleveland, Ohio, thalassemia is a genetic blood disorder that affects the body's ability to produce healthy haemoglobin, the oxygen-carrying component of red blood cells. This results in chronic anemia, fatigue, developmental delays, bone deformities, and in severe cases, life-threatening complications. US Centers for Disease Control and Prevention (CDC) classifies Thalassemia based on which part of the haemoglobin molecule is affected, alpha or beta, and the severity of the condition, described as trait, intermedia, or major. Thalassemia types are classified based on which part of the hemoglobin molecule is affected—alpha or beta—and the severity of the condition, described as trait, intermedia, or major. Hemoglobin, responsible for carrying oxygen throughout the body, consists of alpha and beta protein chains. When the body can't produce enough of either, it leads to alpha or beta thalassemia, resulting in reduced hemoglobin levels and varying degrees of anemia. According to severity: How common is thalassemia in India and how is it diagnosed? According to a new study by Metropolis Healthcare, an Indian multinational diagnostic, more than 1 in 4 Indian children clinically suspected of inherited blood disorders found positive. The study highlighted that over 51 per cent of affected children were under age 3, reinforcing the urgent need for prenatal and early childhood screening. 'Our findings reveal an urgent public health concern. Early detection through prenatal and newborn screening can dramatically alter disease outcomes,' said Dr Smita Sudke, Chief of Laboratory, Metropolis Healthcare. Advanced molecular techniques like Next-Generation Sequencing (NGS), Gap-PCR, and Sanger sequencing now make it possible to detect mutations with high precision, even before symptoms appear. 'NGS is a game-changer for identifying rare and novel mutations. It helps decode unexplained symptoms and enables early, even pre-symptomatic, diagnosis,' said Dr Kirti Chadha, Chief Scientific and Innovation Officer, Metropolis Healthcare. Metropolis' earlier study of 65,779 cases across revealed how modern DNA sequencing is improving diagnosis and disease classification, especially for beta-thalassemia. Why premarital and prenatal screening matter in thalassemia Despite the high burden, premarital screening remains rare in India due to social stigma. However, antenatal testing is gaining ground in high-risk groups. Doctors stress the importance of screening both partners before pregnancy. If both are carriers, there's a 25 per cent chance of the child having thalassemia major, a severe, lifelong condition. How is thalassemia treated in India today? Standard treatment in India includes: Regular blood transfusions Iron chelation therapy to remove excess iron Bone marrow transplant (BMT): A potential cure if a matched donor is available Gene therapy: Experimental in India, but now a realistic hope According to Dr Rahul Bhargava, Principal Director & Chief of BMT at Fortis Memorial Research Institute, 'A matched bone marrow transplant offers a curative option. But gene therapy could transform how we approach thalassemia treatment in the future.' What is the cost burden of thalassemia care in India? Annual cost of treatment ranges between ₹1.5–4 lakhs for transfusions and medications Bone Marrow Transplant costs ₹10–25 lakhs (some public hospitals subsidise) Gene therapy is currently unavailable in India and is expected to be expensive initially Can thalassemia be prevented through screening and awareness? According to experts, yes, prevention is possible through: Carrier screening Prenatal testing Genetic counseling Dr Sudke adds, 'We must integrate genetic screening into routine maternal and child health programs. It's the most effective way to reduce the future burden.' What does the gene therapy success in China mean for India?
New Indian Express
28-05-2025
- New Indian Express
TN to set up centres of excellence for genetic disorder prevention in Coimbatore, Madurai
COIMBATORE: The state health department with the support of National Health Mission (NHM) is preparing to launch Centers of Excellence for the prevention and management of genetic disorders in Coimbatore and Madurai, following the footsteps of Chennai. These centers aim to facilitate genetic research and laboratory tests for conditions such as inborn errors of metabolism and immune deficiencies. Construction of the buildings and procurement of high-value machinery are currently underway, said officials and added that 50% of the work has been completed. Recognising that genetic disorders are a major cause of Infant Mortality Rate (IMR) and Under-Five Mortality Rate (U5MR), the state government has allocated Rs 8.19 crore to establish two new Centres of Excellence in Coimbatore and Madurai, said officials. "The center is already operational at the Institute of Child Health and Hospital for Children (ICH) in Chennai. Efforts to launch similar centers at government medical college hospitals in Coimbatore and Madurai are in progress," said Expert Advisor for Child Health, National Health Mission, Tamil Nadu S Srinivasan. The centers will specialise in a variety of genetic disorders, including hemoglobinopathies like thalassemia and sickle cell anemia, chromosomal disorders, spinal muscular atrophy (SMA), Duchenne muscular dystrophy (DMD), other neuromuscular disorders, lysosomal storage diseases (LSD), mucopolysaccharidosis (MPS), congenital adrenal hyperplasia, congenital hypothyroidism, glucose-6-phosphate dehydrogenase (G-6PD) deficiency, and cystic fibrosis, as outlined in the government order. "We have acquired expensive machinery such as Tandem Mass Spectrometry (TMS) and Next-Generation Sequencing (NGS) for genetic testing, among other equipments, at the ICH in Chennai. With this laboratory, we can screen patients with genetic disorders, diagnose their conditions, and explore potential solutions. For example, inborn errors of metabolism (IEM) are rare genetic conditions that impair the body's ability to convert food into energy due to enzyme defects. Using TMS, we can screen and diagnose IEMs," Dr Srinivasan added.
